Mk-677 Vs Cjc-1295 Ipamorelin
MK-677 vs CJC-1295 Ipamorelin
The short answer
MK-677 is an oral, once-daily ghrelin mimetic; CJC-1295 plus ipamorelin is an injectable pairing of a GHRH analog and a selective growth hormone secretagogue (Nass et al., 2008; Teichman et al., 2006; Raun et al., 1998).
This page is general educational information, research-use framing only, not medical advice. Any decision about a research compound belongs with a qualified clinician.
What is the core difference between MK-677 and CJC-1295 plus ipamorelin?
MK-677 is a single oral ghrelin-receptor mimetic taken once daily, while CJC-1295 plus ipamorelin is a two-compound injectable pairing that combines a GHRH analog with a selective GH secretagogue.
These molecules all aim to raise the body's own growth hormone (GH) output, but they do it through different receptors and different routes. MK-677 (ibutamoren) mimics ghrelin and works orally, which is its main appeal for research interest (Nass et al., 2008). CJC-1295 is a GHRH analog studied for its ability to sustain GH and IGF-1 elevation (Teichman et al., 2006). Ipamorelin acts on the ghrelin/GH secretagogue receptor and was reported to trigger GH release with high selectivity, meaning little effect on cortisol or prolactin (Raun et al., 1998). The pairing is often studied together because a GHRH analog and a GH secretagogue act on separate pathways.
What did the research report on MK-677?
In a 12-month randomized trial, MK-677 at 25 mg/day raised fat-free mass by about 1.1 kg but also raised fasting blood glucose and reduced insulin sensitivity (Nass et al., 2008).
The Nass et al. (2008) study in Annals of Internal Medicine examined older adults in a randomized trial that measured body composition at the 12-month mark, a long window for a GH secretagogue study. The reported gain in fat-free mass at that point was modest at roughly 1.1 kg. The same study flagged the metabolic trade-off: fasting glucose rose and insulin sensitivity fell. That glucose signal is the single most important caution in the MK-677 literature and is why researchers watching metabolic markers treat it carefully.
What did the research report on CJC-1295 and ipamorelin?
CJC-1295 sustained raised GH and IGF-1 levels in early human dosing work (Teichman et al., 2006), and ipamorelin was described as a selective GH secretagogue in preclinical study (Raun et al., 1998).
Teichman et al. (2006), published in the Journal of Clinical Endocrinology and Metabolism, reported that CJC-1295 produced dose-dependent, sustained increases in GH and IGF-1 after single doses. Raun et al. (1998), in the European Journal of Endocrinology, characterized ipamorelin as releasing GH without the unwanted rise in cortisol or prolactin seen with some earlier secretagogues. Human clinical data on the combined pair used together for body-composition endpoints remains limited compared with the year-long MK-677 dataset, so much of the pairing rationale rests on their separate mechanisms rather than large combined trials.
How do route, half-life, and metabolic profile compare?
MK-677 is oral and once-daily with a documented glucose caution, while CJC-1295 plus ipamorelin is injectable with a reported profile of hormonal selectivity but less long-term human data.
| Feature | MK-677 (ibutamoren) | CJC-1295 | Ipamorelin |
|---|---|---|---|
| Class | Oral ghrelin mimetic | GHRH analog | GH secretagogue |
| Route studied | Oral, once daily (Nass et al., 2008) | Injectable (Teichman et al., 2006) | Injectable (Raun et al., 1998) |
| Research-reported dose | 25 mg/day over 12 months (Nass et al., 2008) | Dose-dependent single-dose escalation studied (Teichman et al., 2006) | Preclinical characterization (Raun et al., 1998) |
| Key reported effect | Fat-free mass +1.1 kg (Nass et al., 2008) | Sustained GH and IGF-1 rise (Teichman et al., 2006) | Selective GH release, low cortisol/prolactin (Raun et al., 1998) |
| Metabolic caution | Raised fasting glucose, lowered insulin sensitivity (Nass et al., 2008) | Human safety data limited | Human safety data limited |
| Human data depth | 12-month randomized trial (Nass et al., 2008) | Early clinical dosing (Teichman et al., 2006) | Preclinical (Raun et al., 1998) |
The dose figures above describe what published research reported, not a protocol. Any personal dosing question belongs with a qualified clinician.
Which factors matter most when researchers compare these two options?
The decision usually turns on three things: route preference, tolerance for the MK-677 glucose signal, and how much long-term human evidence a researcher wants behind the choice.
Route is the plainest split. MK-677 is a daily oral compound, while CJC-1295 plus ipamorelin requires injection. On evidence depth, MK-677 has the longer human record here, a 12-month randomized trial (Nass et al., 2008), whereas the injectable pair rests on shorter or separate studies (Teichman et al., 2006; Raun et al., 1998). On metabolic safety, the MK-677 glucose and insulin-sensitivity signal is documented (Nass et al., 2008), while the injectable pair's reported selectivity is a mechanistic point, not proof of a cleaner long-term outcome, because long-term combined human data is limited.
Are these compounds approved for weight loss or anti-aging?
No; none of these three compounds is an approved weight-loss or anti-aging therapy, and they are discussed here strictly as research compounds.
Growth hormone secretagogues are studied for how they influence GH and IGF-1, body composition markers, and metabolic endpoints, but that is a research context, not an approval. Statements here describe what studies report, not outcomes any reader should expect. Anyone weighing these compounds for a personal reason should speak with a qualified clinician.
Keep reading
Related research and verification
Mk-677 Vs Cjc-1295 Ipamorelin: FAQ
Sourcing research-grade peptides?
Talk to the Peptara Labs team about purity, third-party certificates of analysis, and cold-chain shipping.
References
- Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized, controlled trial. Annals of Internal Medicine. 2008;149(9):601-611 (PMID 18981485). Two-year randomized trial (body composition reported at the 12-month mark) in older adults where MK-677 at 25 mg per day raised fat-free mass by about 1.1 kg but also raised fasting glucose and lowered insulin sensitivity.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805. doi:10.1210/jc.2005-1536 (PMID 16352683). Early human dosing work reporting dose-dependent, sustained increases in GH and IGF-1 after single doses of CJC-1295.
- Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. doi:10.1530/eje.0.1390552 (PMID 9849822). Characterization of ipamorelin as a selective GH secretagogue that released GH without a strong rise in cortisol or prolactin.
General educational information only, research-use framing, not medical advice. Confirm the current status where you live and consult a qualified professional before acting.